S&P 500   3,273.44 (-0.09%)
DOW   28,734.78 (+0.04%)
QQQ   221.81 (+0.16%)
AAPL   324.32 (+2.09%)
FB   223.23 (+2.50%)
MSFT   168.04 (+1.56%)
AMZN   1,858.00 (+0.26%)
CGC   23.52 (-1.67%)
NVDA   245.54 (-0.98%)
BABA   212.09 (+0.88%)
MU   55.30 (-2.07%)
TSLA   580.99 (+2.49%)
AMD   47.51 (-5.98%)
T   37.05 (-3.97%)
ACB   1.93 (-2.03%)
F   8.86 (-1.34%)
NFLX   343.16 (-1.54%)
DIS   136.07 (-1.66%)
GILD   64.30 (-0.09%)
S&P 500   3,273.44 (-0.09%)
DOW   28,734.78 (+0.04%)
QQQ   221.81 (+0.16%)
AAPL   324.32 (+2.09%)
FB   223.23 (+2.50%)
MSFT   168.04 (+1.56%)
AMZN   1,858.00 (+0.26%)
CGC   23.52 (-1.67%)
NVDA   245.54 (-0.98%)
BABA   212.09 (+0.88%)
MU   55.30 (-2.07%)
TSLA   580.99 (+2.49%)
AMD   47.51 (-5.98%)
T   37.05 (-3.97%)
ACB   1.93 (-2.03%)
F   8.86 (-1.34%)
NFLX   343.16 (-1.54%)
DIS   136.07 (-1.66%)
GILD   64.30 (-0.09%)
S&P 500   3,273.44 (-0.09%)
DOW   28,734.78 (+0.04%)
QQQ   221.81 (+0.16%)
AAPL   324.32 (+2.09%)
FB   223.23 (+2.50%)
MSFT   168.04 (+1.56%)
AMZN   1,858.00 (+0.26%)
CGC   23.52 (-1.67%)
NVDA   245.54 (-0.98%)
BABA   212.09 (+0.88%)
MU   55.30 (-2.07%)
TSLA   580.99 (+2.49%)
AMD   47.51 (-5.98%)
T   37.05 (-3.97%)
ACB   1.93 (-2.03%)
F   8.86 (-1.34%)
NFLX   343.16 (-1.54%)
DIS   136.07 (-1.66%)
GILD   64.30 (-0.09%)
S&P 500   3,273.44 (-0.09%)
DOW   28,734.78 (+0.04%)
QQQ   221.81 (+0.16%)
AAPL   324.32 (+2.09%)
FB   223.23 (+2.50%)
MSFT   168.04 (+1.56%)
AMZN   1,858.00 (+0.26%)
CGC   23.52 (-1.67%)
NVDA   245.54 (-0.98%)
BABA   212.09 (+0.88%)
MU   55.30 (-2.07%)
TSLA   580.99 (+2.49%)
AMD   47.51 (-5.98%)
T   37.05 (-3.97%)
ACB   1.93 (-2.03%)
F   8.86 (-1.34%)
NFLX   343.16 (-1.54%)
DIS   136.07 (-1.66%)
GILD   64.30 (-0.09%)
Log in

NYSEAMERICAN:PFNX - Pfenex Stock Price, Forecast & News

$11.30
+0.13 (+1.16 %)
(As of 01/29/2020 04:00 PM ET)
Today's Range
$10.80
Now: $11.30
$11.46
50-Day Range N/A
52-Week Range
$3.40
Now: $11.30
$13.95
Volume175,528 shs
Average Volume334,844 shs
Market Capitalization$357.94 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Pfenex Inc, a clinical-stage development and licensing biotechnology company, focuses on developing protein therapies for unmet patient needs. Its lead product candidates include PF708, a therapeutic equivalent drug candidate to Forteo (teriparatide) for the treatment of osteoporosis; and novel anthrax vaccine candidates, such as Px563L and RPA563 that have completed Phase Ia clinical study. Read More…

Industry, Sector and Symbol

Stock Exchange NYSEAMERICAN
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Current SymbolNYSEAMERICAN:PFNX
Previous SymbolNYSEMKT:PFNX
CUSIPN/A
CIKN/A
Phone+1-858-3524400

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees71
Market Cap$357.94 million
Next Earnings Date3/9/2020 (Estimated)
OptionableOptionable

Receive PFNX News and Ratings via Email

Sign-up to receive the latest news and ratings for PFNX and its competitors with MarketBeat's FREE daily newsletter.


Pfenex (NYSEAMERICAN:PFNX) Frequently Asked Questions

What is Pfenex's stock symbol?

Pfenex trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "PFNX."

How were Pfenex's earnings last quarter?

Pfenex Inc (NYSEAMERICAN:PFNX) issued its quarterly earnings data on Thursday, November, 7th. The biotechnology company reported $0.09 earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of $0.09. The biotechnology company had revenue of $15.25 million for the quarter, compared to the consensus estimate of $14.80 million. View Pfenex's Earnings History.

When is Pfenex's next earnings date?

Pfenex is scheduled to release their next quarterly earnings announcement on Monday, March 9th 2020. View Earnings Estimates for Pfenex.

What price target have analysts set for PFNX?

4 brokerages have issued twelve-month price targets for Pfenex's shares. Their forecasts range from $19.00 to $20.00. On average, they expect Pfenex's stock price to reach $19.50 in the next year. This suggests a possible upside of 72.6% from the stock's current price. View Analyst Price Targets for Pfenex.

What is the consensus analysts' recommendation for Pfenex?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pfenex in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Pfenex.

Has Pfenex been receiving favorable news coverage?

News coverage about PFNX stock has trended very positive on Wednesday, according to InfoTrie Sentiment Analysis. The research firm identifies negative and positive press coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Pfenex earned a coverage optimism score of 3.3 on InfoTrie's scale. They also gave media coverage about the biotechnology company a news buzz of 2.0 out of 10, meaning that recent press coverage is very unlikely to have an effect on the stock's share price in the next several days. View News Stories for Pfenex.

Who are some of Pfenex's key competitors?

What other stocks do shareholders of Pfenex own?

Who are Pfenex's key executives?

Pfenex's management team includes the folowing people:
  • Mr. Evert B. Schimmelpennink, CEO, Pres, Sec. & Director (Age 47)
  • Ms. Patricia Lady C.M.A., CPA, M.B.A., CPA, MBA CMA, Chief Accounting Officer (Age 61)
  • Mr. Patrick K. Lucy, Chief Bus. Officer (Age 51)
  • Dr. Hubert C. Chen, Advisor (Age 50)
  • Ms. Susan A. Knudson, Chief Financial Officer (Age 55)

Who are Pfenex's major shareholders?

Pfenex's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Sanders Morris Harris LLC (1.31%), Calamos Advisors LLC (0.31%), California Public Employees Retirement System (0.25%), Strs Ohio (0.16%) and Falcon Point Capital LLC (0.11%). Company insiders that own Pfenex stock include Evert B Schimmelpennink, Patrick K Lucy, Phillip M Schneider and Robin Campbell. View Institutional Ownership Trends for Pfenex.

Which major investors are selling Pfenex stock?

PFNX stock was sold by a variety of institutional investors in the last quarter, including Strs Ohio and Falcon Point Capital LLC. View Insider Buying and Selling for Pfenex.

Which major investors are buying Pfenex stock?

PFNX stock was purchased by a variety of institutional investors in the last quarter, including Sanders Morris Harris LLC, Calamos Advisors LLC and California Public Employees Retirement System. Company insiders that have bought Pfenex stock in the last two years include Evert B Schimmelpennink, Phillip M Schneider and Robin Campbell. View Insider Buying and Selling for Pfenex.

How do I buy shares of Pfenex?

Shares of PFNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Pfenex's stock price today?

One share of PFNX stock can currently be purchased for approximately $11.30.

How big of a company is Pfenex?

Pfenex has a market capitalization of $357.94 million. Pfenex employs 71 workers across the globe.View Additional Information About Pfenex.

What is Pfenex's official website?

The official website for Pfenex is http://www.pfenex.com/.

How can I contact Pfenex?

Pfenex's mailing address is 10790 Roselle St, SAN DIEGO, CA 92121-1508, United States. The biotechnology company can be reached via phone at +1-858-3524400.


MarketBeat Community Rating for Pfenex (NYSEAMERICAN PFNX)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  198 (Vote Outperform)
Underperform Votes:  203 (Vote Underperform)
Total Votes:  401
MarketBeat's community ratings are surveys of what our community members think about Pfenex and other stocks. Vote "Outperform" if you believe PFNX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PFNX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/29/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel